01162nas a2200205   4500000000100000008004100001260001200042653003000054653003000084653001900114653001600133100001200149700001300161245008100174856005800255300001200313490000700325520061000332022001400942       2020                            d  c01/202010aErythema nodosum leprosum10aerythema nodosum leprosum10alepra reaction10athalidomide1 aBhat RM1 aVaidya T00aWhat is New in the Pathogenesis and Management of Erythema Nodosum Leprosum.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413435/  a482-4920 v113 a<p>Erythema nodosum leprosum (ENL) is a manifestation of type II lepra reaction, seen in lepromatous or borderline lepromatous leprosy. Although it is a common reaction encountered in clinical practice, there are an increasingly large number of newer updates in the pathophysiology and management of this condition. The treatment options have expanded far beyond just thalidomide and steroids and now extends to TNF-α inhibitors, thalidomide analogs, tenidap, cyclosporine A, plasma exchange, and even IVIG amongst others. These updates and the current knowledge of ENL are summarized in this review.</p>  a2229-5178